MRI-Guided SBRT Reduces GI Toxicities in Prostate Cancer

Patients who received MRI-guided stereotactic body radiotherapy for prostate cancer experienced fewer moderate acute physician-scored genitourinary and gastrointestinal adverse effects compared with those who received computed tomography–guided stereotactic body radiotherapy.

Amar U. Kishan, MD, discusses interim results from the phase 3 MIRAGE trial of magnetic resonance imaging–guided stereotactic body radiotherapy in prostate cancer.

Amar U. Kishan, MD, discusses the safety results of MRI-guided SBRT compared with the current standard of care, highlights the benefits of using an MRI to guide radiation for patients with prostate cancer, and explains other areas where MRI-guided SBRT could explored.

Dr Kishan discusses the use of MRI-guided SBRT in prostate cancer to reduce acute genitourinary and gastrointestinal toxicity; findings from the MIRAGE study; and how MRI-guided SBRT allows for tighter planning margins, thereby reducing both physician-reported and patient-reported bowel and bladder toxicities.